BG
ALMR

Bellevue Group’s Alamar Biosciences ALMR Stock Holding History

Bellevue Group’s Portfolio ALMR Stock Details ALMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.51M Buy
+55,738
New +$1.26M 0.03% 97

Other funds holding ALMR

SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

Bellevue Group's ALMR Position: Q2 2026 in Review

Bellevue Group opened a new position in Alamar Biosciences (ALMR) in Q2 2026: 55,738 shares worth $1.51M. The stake represents 0.03% of the portfolio and ranks #97 among its holdings.

66 funds tracked by Wall St. Rank hold ALMR as of Q2 2026.

  • Bellevue Group held 55,738 shares of Alamar Biosciences worth $1.51M as of Q2 2026.
  • Alamar Biosciences was a new Bellevue Group position in Q2 2026.
  • Alamar Biosciences made up 0.03% of Bellevue Group's portfolio in Q2 2026, its #97 holding.
  • 66 funds tracked by Wall St. Rank held Alamar Biosciences as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.